Who Owns Health Catalyst Company?

Health Catalyst Bundle

Get Full Bundle:

	PESTLE	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Health Catalyst?

Understanding Health Catalyst's ownership is key to grasping its strategy and influence in healthcare tech. Its IPO in July 2019 significantly shifted its ownership from private to public.

Founded in 2008, Health Catalyst aims to drive data-informed healthcare improvements. Their cloud-based data operating system and analytics applications are used by over 1,000 organizations.

As of December 31, 2024, Health Catalyst reported $307 million in revenue. The company's public trading on Nasdaq (HCAT) means ownership is now spread across institutional investors, mutual funds, and individual shareholders. This structure reflects the company's growth and market presence, offering tools like those detailed in a Health Catalyst PESTEL Analysis.

Health Catalyst was established in 2008 by Steven Barlow and Thomas Burton. Thomas Burton, a co-founder, previously led significant process improvement and IT advancements at Intermountain Healthcare. Steven Barlow also holds a co-founder title and executive role within the company. While specific initial ownership percentages are not public, early funding rounds offer insight into the initial stakeholders.

Founding Team Steven Barlow and Thomas Burton founded Health Catalyst in 2008. Thomas Burton brought extensive experience in healthcare IT and process improvement. Early Funding Rounds The company secured Series A funding from Sequoia Capital in September 2011. Subsequent Series B rounds in 2013 attracted significant investment from venture capital firms. Key Early Investors Norwest Venture Partners led a $33 million Series B round in January 2013. Sorenson Capital and Sequoia Capital also participated in this round. Strategic Investment Expansion An expansion of the Series B funding in March 2013 added $8 million from Kaiser Permanente Ventures and CHV Capital. These investments underscored the company's growth trajectory. Early Venture Capital Backing The founders pursued capital from prominent venture capital firms to drive expansion in healthcare analytics. This strategy aimed to solidify market presence and product development. Initial Outside Equity Dan Burton, the current CEO, was involved from the company's early stages. HB Ventures, co-founded by Dan Burton, was the first external equity holder.

The early ownership structure of Health Catalyst was shaped by its founders, Steven Barlow and Thomas Burton, and the venture capital firms that provided crucial early-stage funding. These investors, including Sequoia Capital, Norwest Venture Partners, Sorenson Capital, Kaiser Permanente Ventures, and CHV Capital, played a significant role in the company's initial growth and development. Dan Burton's involvement through HB Ventures as the first outside equity holder also highlights an early strategic partnership that supported the company's expansion in the healthcare analytics sector. Understanding these foundational relationships is key to grasping the initial Health Catalyst ownership. The company's journey from a three-person startup to its current standing reflects the strategic capital infusion and the vision of its early backers, contributing to the overall Health Catalyst company ownership narrative.

Founders and Early Investors

Health Catalyst was founded in 2008 by Steven Barlow and Thomas Burton. Early funding rounds saw significant participation from prominent venture capital firms, shaping the initial Health Catalyst ownership structure.

• Founders: Steven Barlow and Thomas Burton
• Series A Investor: Sequoia Capital (September 2011)
• Series B Lead Investor: Norwest Venture Partners ($33 million, January 2013)
• Other Series B Participants: Sorenson Capital, Sequoia Capital
• Series B Expansion Investors: Kaiser Permanente Ventures, CHV Capital ($8 million, March 2013)
• First Outside Equity Holder: HB Ventures (co-founded by Dan Burton)

Health Catalyst SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Health Catalyst's journey to its current ownership structure was significantly shaped by its initial public offering (IPO) on July 25, 2019. This event marked a pivotal moment, transitioning the company from private to public ownership and making its stock available on the Nasdaq Global Select Market under the ticker symbol 'HCAT'.

Following its IPO, Health Catalyst's ownership landscape has been increasingly influenced by institutional investors. While specific holdings fluctuate and are detailed in quarterly SEC filings, subsequent funding rounds have further diversified its shareholder base. The company's financial position as of the end of Q4 2024 included $392 million in cash, cash equivalents, and short-term investments, alongside 62.4 million weighted average shares outstanding for Q4 2024 adjusted basic net income per share calculations.

Key Stakeholders and Shareholder Dynamics

Institutional investors play a significant role in Health Catalyst's company ownership. Understanding these major shareholders is crucial for comprehending who controls Health Catalyst company.

• The IPO in 2019 was a key event for Health Catalyst stock ownership.
• Subsequent public offerings in 2020 and 2021 expanded the Health Catalyst investors base.
• Institutional investors are now prominent among Health Catalyst major shareholders.
• The company's financial health, as indicated by its cash reserves, supports its public trading status, making it clear that Health Catalyst is publicly traded.
• For a deeper understanding of the company's origins, refer to the Brief History of Health Catalyst.

Health Catalyst PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors for Health Catalyst is composed of individuals bringing diverse expertise, including representation from significant shareholders and founders. Recent changes in late 2024 and early 2025 saw the addition of Dr. Jill Hoggard Green as of December 1, 2024, and the departure of Anita Pramoda on March 1, 2025, after a tenure of nearly ten years.

Health Catalyst operates with a standard one-share-one-vote system, common for publicly traded entities. The company's governance structure and shareholder voting rights are detailed in its proxy filings. For the 2025 Annual Meeting of Stockholders, scheduled for July 9, 2025, shareholders of record as of May 15, 2025, are eligible to vote. The definitive proxy statement (DEF 14A), filed on May 19, 2025, provides comprehensive information on board member backgrounds and any specific voting arrangements. There have been no significant proxy contests or activist campaigns impacting Health Catalyst's decision-making processes recently.

Understanding Health Catalyst's Board and Voting Power

The board's composition is key to understanding Health Catalyst company ownership. Key individuals guide strategic direction, reflecting a blend of insider and external perspectives.

• Board members often represent major Health Catalyst investors.
• The CEO, Dan Burton, also holds a board seat.
• Voting power follows a one-share-one-vote principle.
• Proxy statements offer detailed Health Catalyst stock ownership insights.
• Understanding the Marketing Strategy of Health Catalyst can also shed light on board priorities.

Health Catalyst Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, the ownership trends of Health Catalyst have been shaped by strategic acquisitions and shareholder value initiatives. The company has been active in expanding its capabilities and returning capital to investors.

In a move reflecting confidence in its future prospects, Health Catalyst announced a stock repurchase of approximately $5 million in March 2025. This buyback, part of a larger $40 million program approved in August 2022, retired about 1.1 million shares. The company anticipates continued revenue growth in 2025, projecting total revenue around $335 million and Adjusted EBITDA near $41 million. This dual approach of strategic acquisitions and share repurchases aligns with broader industry trends favoring consolidation and data-driven improvements in healthcare.

Strategic Growth Through Acquisition

Health Catalyst has been actively acquiring companies to enhance its patient engagement and activation capabilities. The recent acquisition of Upfront Healthcare Services for $86 million in early 2025 underscores this strategy.

Shareholder Value Enhancement

The company is also focused on returning value to shareholders through stock repurchases. The $5 million buyback in March 2025 signals management's belief in the company's undervalued stock.

Financial Outlook for 2025

Health Catalyst projects significant revenue growth for 2025, with total revenue anticipated to reach approximately $335 million. This growth is expected to be accompanied by an Adjusted EBITDA of around $41 million.

Industry Consolidation Trends

The company's strategic moves occur within a healthcare landscape increasingly characterized by institutional ownership and consolidation. Understanding these dynamics is crucial for analyzing Competitors Landscape of Health Catalyst.

Health Catalyst Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔